4503.T · Tokyo Stock Exchange

ASTELLAS PHARMA

Compare this company’s P/E and P/S using trailing results and the latest quarter. Ratios are calculated here from market capitalisation, signed ordinary or common-shareholder earnings and revenue.

Market cap US$25.47bnFinancials dated 31 December 2025Price dated 2 October 2026

Core valuation

Trailing P/E12.45×
Latest-quarter run-rate P/E10.02×
Trailing P/S1.95×
Latest-quarter run-rate P/S1.76×

Calculation inputs

Trailing earnings
US$2.04bn
Latest-quarter run-rate earnings
US$2.54bn
Latest fiscal-year earnings
US$321.36m
Trailing revenue
US$13.05bn
Latest-quarter run-rate revenue
US$14.47bn
Latest fiscal-year revenue
US$12.11bn

Featured ETF and mutual-fund exposure

These public funds report this company in their latest disclosed holdings.

Sources and limitations

Financial inputs are attributed to J-Quants. Market cap is calculated locally where auditable price and share inputs are available. Missing data stays missing; losses are retained as signed values and produce a numeric signed P/E.

Open financial source

Financials as of 31 December 2025. Informational research, not investment advice.